Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
June 2024
The global life science instrumentation market size is predicted to increase from USD 67.19 billion in 2024, grew to USD 70.69 billion in 2025 and is anticipated to reach around USD 111.55 billion by 2034, poised to grow at a CAGR of 5.20% between 2024 and 2034. The North America life science instrumentation market size is calculated at USD 20.16 billion in 2024 and is estimated to grow at a fastest CAGR of 5.37% during the forecast year.
The global life science instrumentation market size accounted for USD 67.19 billion in 2024 and is anticipated to reach around USD 111.55 billion by 2034, expanding at a CAGR of 5.20% from 2024 to 2034.
The U.S. life science instrumentation market size reached USD 14.11billion in 2022 and is priicted to be worth around USD 23.99 billion by 2034, at a CAGR of 5.45% from 2024 to 2034.
Based on the region, the North America segment dominated the global life science instrumentation market in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. The life science instrumentation is employed in a variety of applications in North America. The life science instrumentation has shown to be a useful tool for a variety of applications including pharmaceutical applications, final product testing, and food safety testing.
On the other hand, in the life science instrumentation market, the Asia-Pacific region is one of the most profitable regions. The region’s growth is being fueled by strategic expansions by important market players in rising Asian countries, the growing pharmaceutical industry in China and India.
The life science instruments are commonly utilized for analytical techniques and method validation during drug development. Nowadays, several innovative technologies are used in the medication development process. The life science instrumentation market will benefit from rising demand for analytical instruments, strong growth in the biotechnology and pharmaceutical industries, and expanding application area of analytical instruments. As sequencing technologies aids in determining the origin of an illness, increased attention on next generation sequencing (NGS) is expected to promote market growth.
The life science instrumentation market is expected to benefit from an increase in research and development activities in various sectors such as biotechnology, pharmaceuticals, food and beverage, and agriculture. Moreover, the increased number of novel product launches by numerous prominent players is expected to boost the growth of the life science instrumentation market during the forecast period.
The growing incidence of chronic diseases in both developing and developed countries is projected to increase the demand for effective technology for early disease diagnosis, which will drive up the demand for instruments in life science. Furthermore, the market for life science instrumentation is being driven by increased public-private investments in life science research and technical developments in analytical equipment. However, the high cost of life science instrumentation is inhibiting the market’s expansion.
During the forecast period, the life science instrumentation market is expected to rise due to rising demand for effective diagnostic technologies and increasing government funding in the development of new instruments utilized in the life sciences and medical devices sectors. The growing applications of life science instruments in other industries, such as the food and beverage industry is expected to boost the life science instrumentation market growth during the forecast period.
The majority of life science and analytical technologies are utilized to study DNA in order to develop new pharmaceutical medications and determine food quality. The companies are heavily investing in this area in order to increase the market growth. The development of new products will improve the ability to accurately diagnose samples. It will assist in the targeting of treatment for a specific patient.
The growth of life science instrumentation market is projected to be hampered by high maintenance and operation costs. In addition, without an alternative, diagnosing the samples will be difficult because the lack of such intricate equipment would make the process much more complicated and cause the outcome to be delayed.
| Report Coverage | Details |
| Market Size in 2024 | USD 67.19 Billion |
| Market Size in 2034 | USD 111.55 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 5.20% |
| Revenue Projection by 2032 | US$ 100.79 Billion |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, Application, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
The spectroscopy segment led the market in 2024, mainly because of its essential role in detecting, identifying, and quantifying molecules in research, clinical, and diagnostic applications. As a fundamental tool for analyzing molecular composition, structure, and electronic properties, spectroscopy is crucial across life sciences. The pharmaceutical and biotech industries rely heavily on spectroscopy for drug development, quality control, and process monitoring. Growing research funding, especially in academic institutions, is increasing demand for advanced spectroscopic equipment.
The Next-Generation Sequencing (NGS) segment is the fastest-growing, owing to its high throughput, scalability, and speed, which enable rapid sequencing of millions of DNA fragments simultaneously. This capability has expanded genomics research, particularly in disease diagnostics, personalized medicine, and drug discovery. NGS technologies are scalable and adaptable, allowing researchers to modify sequencing capacity from small targeted panels to whole-genome sequencing, applicable across cancer genomics, infectious disease analysis, microbiome studies, and more.
The clinical and diagnostic applications segment dominated the life science instrumentation market in 2024. This dominance was driven by the increasing prevalence of chronic diseases, a growing demand for personalized medicine, and technological advancements in diagnostics. There is a strong need for faster, more accurate, and more efficient diagnostic tools in both research and clinical settings. The shift towards personalized medicine, which customizes treatment for individual patients, heavily relies on diagnostic tools for genetic profiling, biomarker identification, and disease stratification. Rising healthcare expenditures and the adoption of advanced technologies in developing countries are also contributing to the demand for clinical and diagnostic instrumentation.
The drug discovery and development segment is the fastest-growing area in the market during the forecast period. This growth is primarily due to advancements in technologies such as artificial intelligence, machine learning, and high-throughput screening, which accelerate the drug development process and increase the need for specialized instruments. Both governments and private companies are making substantial investments in life science research, particularly in drug discovery and development, leading to a heightened demand for cutting-edge instrumentation. The rise of personalized medicine necessitates specialized tools for analyzing individual patient data and developing tailored therapies, further boosting this segment.
Pharmaceutical and biotechnology companies continued to dominate the market in 2024, driven by significant investments in drug discovery and development, along with a demand for advanced technologies to support these processes. This segment utilizes a wide variety of instruments for numerous applications, including genomics, proteomics, and cell analysis, which drives the demand for innovative technologies and collaborations. Continuous advancements in areas such as next-generation sequencing, surface plasmon resonance (SPR), and chromatography have transformed research and development, making these tools essential for pharmaceutical and biotechnology companies and further contributing to the expansion of this segment.
The contract research organizations (CRO) segment is also experiencing rapid growth. This trend is largely due to the increasing complexity of drug development, rising costs of clinical trials, and the growing demand for clinical trial data, prompting pharmaceutical companies to outsource research and development more frequently. Advancements in areas such as personalized medicine, biologics, and gene therapies have created a need for specialized expertise and infrastructure, which CROs are increasingly offering. Furthermore, hybrid and decentralized trial models enhance patient-centricity but also add complexity to trial execution, further driving the demand for CRO involvement.
By Technology / Instrument Type
By Application
By End-User
By Geography
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
June 2024
January 2025
September 2024
January 2025